India's new cervical cancer pill, SHetA2, has shown potential in clinical trials by preventing HPV from progressing into cancerous cells.
Medical experts caution that while the results are promising, patients should wait for further regulatory approval before considering it a definitive cure.
The therapy, licensed by Emcure and Biological E from ICMR, represents a significant biomedical breakthrough in the fight against HPV-related diseases.